Watch Dr. Sayuk discuss bacterial imbalance and IBS-D , and treatment with XIFAXAN

Gregory S Sayuk, MD, MPH

Associate Professor of Medicine and Psychiatry

Associate Director, Fellowship Training Program

Washington University of St. Louis School of Medicine in St. Louis

Division of Gastroenterology

Watch Dr. Sayuk discuss his clinical experience treating patients with IBS-D

IBS-D, irritable bowel syndrome with diarrhea.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.